Complement Therapeutics - About the company
Complement Therapeutics is a series A company based in London (United Kingdom), founded in 2020 by Paul Bishop, Simon J Clark and Richard Unwin. It operates as a Developer of gene therapies to treat retinal diseases. Complement Therapeutics has raised $84.8M in funding from Gimv and Forbion, with a current valuation of £*****. The company has 128 active competitors, including 46 funded and 27 that have exited. Its top competitors include companies like 4D Molecular Therapeutics, Regenxbio and CureVac.
Company Details
Developer of gene therapies to treat retinal diseases. The company's product line include CTx001 an AAV-based gene therapy for the targeted treatment of Geographic Atrophy due to dry age-related macular degeneration.
- Website
- complementtx.com
- Social
- Email ID
- *****@complementtx.com
Key Metrics
Founded Year
2020
Location
London, United Kingdom
Stage
Series A
Total Funding
$84.8M in 3 rounds
Latest Funding Round
Post Money Valuation
£***** as on Jun 26, 2023
Ranked
11th among 128 active competitors
Employee Count
35 as on Jun 30, 2026
Similar Companies
Legal entities associated with Complement Therapeutics
Complement Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Complement Therapeutics Limited CIN: 12515463 , United Kingdom, Active | Mar 11, 2020 | - | - |
Sign up to download Complement Therapeutics' company profile
Complement Therapeutics's funding and investors
Complement Therapeutics has raised a total funding of $84.8M over 3 rounds. Its first funding round was on 2021. Its latest funding round was a Series A round on Apr 17, 2023 for $*****. 7 investors participated in its latest round. Complement Therapeutics has 8 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of Complement Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 17, 2023 | 6672709 | Series A | 6867573 | 7428432 | 2928756 | 4555669 |
Feb 23, 2022 | 6902380 | Seed | 5893633 | 2064787 | 7265311 | |
2021 | 8284 | Seed | 1591 | 5018 | 9971 |
Access funding benchmarks and valuations. Sign up today!View details of Complement Therapeutics's funding rounds and investors
Complement Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Complement Therapeutics are Paul Bishop, Simon J Clark and Richard Unwin. Rafiq Hasan is the CEO of Complement Therapeutics.
Here are the details of Complement Therapeutics' key team members:
- Paul Bishop: Co-Founder of Complement Therapeutics. They are also an angel investor in 1 startup.
- Simon J Clark: Co-Founder of Complement Therapeutics. Contact Info: 1 email address
- Richard Unwin: Co-Founder of Complement Therapeutics.
- Rafiq Hasan: CEO of Complement Therapeutics. They are also an angel investor in 1 startup.Contact Info: 1 email address
View details of Complement Therapeutics's Founder profiles and Board Members
Complement Therapeutics' employee count trend
Complement Therapeutics has 35 employees as of Jun 26. Here is Complement Therapeutics's employee count trend over the years:
Uncover Complement Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Complement Therapeutics's Competitors and alternates
Top competitors of Complement Therapeutics include 4D Molecular Therapeutics, Regenxbio and CureVac. Here is the list of Top 10 competitors of Complement Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | 4D Molecular Therapeutics 2013, Emeryville (United States), Public | Developer of gene therapeutics for genetic disorders | $187M | 68/100 | |
2nd | Regenxbio 2008, Rockville (United States), Public | Developer of AAV Gene Therapy for rare genetic diseases | $108M | 67/100 | |
3rd | Developer of mRNA-based therapeutics against cancer and infectious diseases | $975M | 67/100 | ||
4th | Kala Pharmaceuticals 2009, Waltham (United States), Public | Developer of ophthalmic treatments based on its mucosal penetrating product platform | $115M | 66/100 | |
5th | MeiraGTx 2015, New York City (United States), Public | Developer of gene therapies for ocular and neurodegenerative diseases | - | 65/100 | |
6th | Rezolute 2012, Denver (United States), Public | Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI) | - | 64/100 | |
7th |  Kriya Therapeutics 2012, Redwood City (United States), Series D | Developer of therapeutic solutions for the treatment of diabetes | $938M | 64/100 | |
8th |  AAVantgarde Bio 2021, Milano (Italy), Series B | Developer of gene therapies using Adeno-Associated Viral vectors | $206M | 63/100 | |
9th | Aviceda Therapeutics 2018, Cambridge (United States), Series C | Developer of biotherapeutics for glycol-immune diseases | $255M | 62/100 | |
10th | Outlook Therapeutics 2011, Cranbury (United States), Public | Developer of antibodies for ophthalmic disorders | $51.8M | 61/100 | |
11th |  Complement Therapeutics 2020, London (United Kingdom), Series A | Developer of gene therapies to treat retinal diseases | $84.8M | 61/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Complement Therapeutics's competitors? Click here to see the top ones
Complement Therapeutics's Investments and acquisitions
Complement Therapeutics has made no investments or acquisitions yet.
Reports related to Complement Therapeutics
Here is the latest report on Complement Therapeutics's sector:
News related to Complement Therapeutics
Media has covered Complement Therapeutics for a total of 3 events in the last 1 year, 1 of them has been about company updates.
•
Complement Therapeutics Announces First Patient Dosed with CTx001 for Geographic AtrophyBusinessnewsthisweek•Mar 25, 2026•Complement Therapeutics
•
•
•
Complement Therapeutics unveils state-of-the-art lab in StevenageBusiness Weekly newspaper•Jun 17, 2023•Complement Therapeutics
•
Complement Therapeutics’ €72 Million Series A Financing RoundGlobal Legal Chronicle•May 29, 2023•Complement Therapeutics, Fieldfisher
•
Manchester University Spinout Secures €72m FundingInsider Media•May 17, 2023•The University of Manchester, Complement Therapeutics
•
Complement Therapeutics Raises €72M in Series A FinancingFinSMEs•Apr 17, 2023•Complement Therapeutics, Seroba Lifesciences, Hadean Ventures, Cambridge Innovation Capital and 5 others
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Complement Therapeutics
Explore our recently published companies
- Quality Home Repair - United States based, 1996 founded, Unfunded company
- Snack Plate Creative - United States based, Unfunded company
- Saiman Healthcare - India based, 2021 founded, Unfunded company
- ArmGenius - Uganda based, 2021 founded, Unfunded company
- Hicks Home - Unfunded company
- Kklouds Media - Mumbai based, 2020 founded, Unfunded company
